TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21672008

Group type: EXPERIMENTAL
Intervention: 3‐h structured education with personalized pedometer use
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 3‐h structured education programme aimed at promoting physical activity
Number of subjects: 98

Group type: COMPARATOR
Intervention: advice leaflet
Number of subjects: 98
Study: 18380936

Group type: EXPERIMENTAL
Intervention: Women with autism and learning disability
Number of subjects: 26

Group type: COMPARATOR
Intervention: Women with non-autism learning disability (Control group)
Number of subjects: 26
Study: 16839346

Group type: EXPERIMENTAL
Intervention: BIBT 986 intravenous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12637979

Group type: EXPERIMENTAL
Intervention: Granulocyte‐Colony Stimulating Factor (G‐CSF) 5 microg/kg daily for 10 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10636257

Group type: EXPERIMENTAL
Intervention: Twice daily metoprolol tartrate (MT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Once daily metoprolol succinate (MS)
Number of subjects: 27
Study: 9020417

Group type: COMPARATOR
Intervention: Antihistamine (mizolastine)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Azelastine nasal spray
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Azelastine (oral application)
Number of subjects: 1070
Study: 1527296

Group type: EXPERIMENTAL
Intervention: Low dose intravenous deslanoside (0.002 mg/kg body weight)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.6 mg of deslanoside (open label assessment)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low dose intravenous deslanoside
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Deslanoside (both doses)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Deslanoside
Number of subjects: 9
Study: 3880585

Group type: EXPERIMENTAL
Intervention: Desamino-D-arginine vasopressin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 37
Study: 29352518

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion (CWI) of 0.2% ropivacaine at 10 ml/h for 48 hours
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (IVL) of 1.5% lidocaine at 4 ml/h for 48 hours
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 28341613

Group type: EXPERIMENTAL
Intervention: Sunscreen with antioxidants (Spirulina and dimethylmethoxy chromanol)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sunscreen without antioxidants (control)
Number of subjects: 44
Study: 26646026

Group type: EXPERIMENTAL
Intervention: Height-adjustable workstations and supporting techniques
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 238
Study: 24251361

Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of warfarin
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Clinically guided dosing of warfarin
Number of subjects: 1015
Study: 20868741

Group type: EXPERIMENTAL
Intervention: buprenorphine
Number of subjects: 17

Group type: COMPARATOR
Intervention: methadone
Number of subjects: 17
Study: 18441707

Group type: EXPERIMENTAL
Intervention: magnerot
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: alprazolam
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo (control group)
Number of subjects: 144
Study: 16778691

Group type: EXPERIMENTAL
Intervention: Cervical epidural steroid injections at C6-C7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical epidural steroid injections at C7-T1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cervical epidural steroid injections at both levels
Number of subjects: 0
Study: 12680863

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo challenge (diluent)
Number of subjects: 16
Study: 11434595

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily, amoxycillin 750 mg three times a day, metronidazole 500 mg three times a day (OAM)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily, amoxycillin 750 mg three times a day, metronidazole 500 mg three times a day (RAM)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: OAM
Number of subjects: 456

Group type: COMPARATOR
Intervention: RAM
Number of subjects: 456
Study: 9629968

Group type: EXPERIMENTAL
Intervention: Freely selected movements (free mode)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed movements (fixed mode)
Number of subjects: 31
Study: 10184179

Group type: EXPERIMENTAL
Intervention: Terminology clarification in physician orders
Number of subjects: 0
Study: 3286439

Group type: EXPERIMENTAL
Intervention: Exifone 600 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exifone 1200 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31859346

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) with and without methotrexate (MTX)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 317
Study: 29561282

Group type: EXPERIMENTAL
Intervention: Postoperative 5-fluorouracil-based adjuvant therapies
Number of subjects: 3714
Study: 27911654

Group type: EXPERIMENTAL
Intervention: WhatsApp social groups
Number of subjects: 82

Group type: COMPARATOR
Intervention: Facebook social groups
Number of subjects: 82
Study: 25041467

Group type: EXPERIMENTAL
Intervention: Steroid plus antiviral agents (S + A group, n = 569)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Steroid alone (S group, n = 773)
Number of subjects: 1342

Group type: EXPERIMENTAL
Intervention: Steroid plus antiviral agents (S + A group)
Number of subjects: 1342

Group type: COMPARATOR
Intervention: Steroid alone (S group)
Number of subjects: 1342
Study: 22260244

Group type: EXPERIMENTAL
Intervention: 0.6 g/kg ethanol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 21599732

Group type: COMPARATOR
Intervention: Combined spinal epidural analgesia
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Low-dose infusion
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: High-dose epidural
Number of subjects: 1054
Study: 18283138

Group type: EXPERIMENTAL
Intervention: 250 mL of 7.5% hypertonic saline and 6% dextran 70 (HSD)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Lactated Ringer solution (LRS)
Number of subjects: 209
Study: 17065882

Group type: EXPERIMENTAL
Intervention: ETT cuff manipulation (cuff maintained at 20 mmHg or less, deflated for 5 seconds and then reinflated)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No manipulation of ETT cuff after intubation (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 12848266

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR)
Number of subjects: 0
Study: 10502592

Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization followed by continued medical therapy
Number of subjects: 275

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 275
Study: 8942248

Group type: EXPERIMENTAL
Intervention: Chloral 40 mg/kg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Trimeprazine 3 mg/kg
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg/kg
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 1781032

Group type: EXPERIMENTAL
Intervention: One-day educational intervention against smoking
Number of subjects: 17446

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 17446
Study: 7138721

Group type: EXPERIMENTAL
Intervention: Sitting position for 2.5 min or more during and after injection of 3 ml of 0.5% isobaric bupivacaine‐HCl
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lateral horizontal position (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: C.S.F. indices (pressure, protein, chloride ion concentration, pH, specific gravity)
Number of subjects: 40
Study: 30718952

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg once daily for 16 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (SFC)
Number of subjects: 0
Study: 28244117

Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM-ON)
Number of subjects: 595

Group type: COMPARATOR
Intervention: Ambulatory Follow-up (RM-OFF)
Number of subjects: 595
Study: 26199168

Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium histolyticum treatment
Number of subjects: 0
Study: 24172265

Group type: EXPERIMENTAL
Intervention: Miniaturized extracorporeal circulation (MECC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard extracorporeal circulation (SECC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 61
Study: 21382866

Group type: EXPERIMENTAL
Intervention: Supported exercise programme (12 weeks)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard care (12 weeks)
Number of subjects: 99
Study: 18808404

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-of-care immunosuppression (Thymoglobulin and/or pulse steroids)
Number of subjects: 20
Study: 17134488

Group type: EXPERIMENTAL
Intervention: Low dose intravenous furosemide 40 mg (Group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose intravenous furosemide 120 mg (Group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 12945021

Group type: EXPERIMENTAL
Intervention: Topical amitriptyline 50 mmol/L
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical amitriptyline 100 mmol/L
Number of subjects: 14

Group type: COMPARATOR
Intervention: Topical amitriptyline 10 mmol/L
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Topical amitriptyline
Number of subjects: 14
Study: 11004739

Group type: EXPERIMENTAL
Intervention: Positive imagery
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Negative imagery
Number of subjects: 72

Group type: COMPARATOR
Intervention: No imagery
Number of subjects: 72
Study: 8842889

Group type: EXPERIMENTAL
Intervention: Interactive Kader method
Number of subjects: 74

Group type: COMPARATOR
Intervention: Didactic methods
Number of subjects: 74
Study: 2064495

Group type: EXPERIMENTAL
Intervention: Niacin 2000 mg
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Niacin 1500 mg
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo and diet treatment
Number of subjects: 201
Study: 6853992

Group type: EXPERIMENTAL
Intervention: Suction biopsy technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Endoscopic biopsy technique
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acid reflux test
Number of subjects: 18

Group type: COMPARATOR
Intervention: Histologic criteria for gastroesophageal reflux
Number of subjects: 18
Study: 3957518

Group type: EXPERIMENTAL
Intervention: Positive work (eta)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Negative work (eta‐)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Integrated electrical activity (IEMG)
Number of subjects: 61
Study: 30792988

Group type: EXPERIMENTAL
Intervention: 800 mg efavirenz
Number of subjects: 132

Group type: COMPARATOR
Intervention: 600 mg efavirenz
Number of subjects: 132
Study: 27357200

Group type: EXPERIMENTAL
Intervention: Young mothers aged ≤16 years
Number of subjects: 4749

Group type: EXPERIMENTAL
Intervention: Primiparous women aged ≤16 years
Number of subjects: 4749

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 4749
Study: 24827136

Group type: EXPERIMENTAL
Intervention: Mitomycin C with maintenance chemotherapy (MMC/Maint)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Cisplatin with maintenance chemotherapy (CisP/Maint)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Mitomycin C without maintenance chemotherapy (MMC/No-maint)
Number of subjects: 940

Group type: EXPERIMENTAL
Intervention: Cisplatin without maintenance chemotherapy (CisP/No-maint)
Number of subjects: 940

Group type: COMPARATOR
Intervention: Cisplatin (CisP)
Number of subjects: 940
Study: 22082108

Group type: EXPERIMENTAL
Intervention: Telemonitoring system usage intention based on the Technology Acceptance Model (TAM)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Modified TAM including Facilitators
Number of subjects: 234
Study: 20480054

Group type: EXPERIMENTAL
Intervention: Zinc citrate dentifrice (1% zinc citrate)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 35
Study: 18711110

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 68
Study: 15877562

Group type: EXPERIMENTAL
Intervention: Behavioral training (biofeedback-assisted pelvic floor muscle exercises)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Drug treatment (oxybutynin IR titrated from 2.5 mg per day to 5.0 mg three times a day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study: 12508333

Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caloric content (high vs low)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Profile status (AP vs NP)
Number of subjects: 0
Study: 10499828

Group type: EXPERIMENTAL
Intervention: Na2 ethylenediaminetetraacetic acid (edta) solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 10
Study: 7489470

Group type: EXPERIMENTAL
Intervention: Mixture of midazolam 0.4 mg.kg‐1 + ketamine 4 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketamine 6 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 60
Study: 1659494

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg QD)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (120 to 480 mg QD)
Number of subjects: 68
Study: 6220476

Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 60
Study: 31968049

Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting pulmonary to systemic flow ratio from chest radiographs
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: Deep learning model
Number of subjects: 657
Study: 30912737

Group type: EXPERIMENTAL
Intervention: Growing Up Milk - Lite (GUMLi)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Cows' milk (control)
Number of subjects: 160
Study: 29503075

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral cefixime
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral levofloxacin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 180
Study: 27034958

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation at 3 g/d for 8 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25144625

Group type: EXPERIMENTAL
Intervention: Higher dose of 50-60 min of aerobic exercise
Number of subjects: 301
Study: 22920807

Group type: EXPERIMENTAL
Intervention: Cooperative exergame (n = 14)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Competitive exergame (n = 17)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cooperative exergame
Number of subjects: 31
Study: 20973739

Group type: EXPERIMENTAL
Intervention: Early SWL (within 48 hours of onset of colicky pain)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Delayed SWL (after 48 hours)
Number of subjects: 160
Study: 17379048

Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 16286521

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (20 to 26 sessions)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Moderate-intensity intervention (six sessions)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-intensity condition (attended more than three-quarters of the sessions)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: High-intensity and moderate-intensity interventions
Number of subjects: 123
Study: 11310134

Group type: EXPERIMENTAL
Intervention: Preventive dental program (PDP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (non-participating children)
Number of subjects: 180
Study: 9248117

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 60
Study: 8136642

Group type: EXPERIMENTAL
Intervention: Xianbai Buyang Huanwu Decoction (XBH)
Number of subjects: 80

Group type: COMPARATOR
Intervention: compound hypotensor tablets and gamma‐evening primrose‐E oil capsules
Number of subjects: 80
Study: 2961085

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Spinal mobilization without rotational forces
Number of subjects: 54
Study: 30931825

Group type: EXPERIMENTAL
Intervention: Combined training group (perceptual‐cognitive simulation training with high physiological load)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Independent training group (perceptual‐cognitive simulation training and physiological load intervention completed independently)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: High physiological load
Number of subjects: 13
Study: 27329522

Group type: EXPERIMENTAL
Intervention: Total volume
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CE volume
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Spherical rim width
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Geometric heterogeneity
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Age-adjusted predictors of OS (spherical rim width)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Age-adjusted predictors of OS (geometric heterogeneity)
Number of subjects: 117
Study: 25440579

Group type: EXPERIMENTAL
Intervention: cTBS of visual area hMT+
Number of subjects: 8

Group type: COMPARATOR
Intervention: cTBS of areas V1/V2
Number of subjects: 8

Group type: COMPARATOR
Intervention: cTBS of the vertex (control)
Number of subjects: 8
Study: 23803341

Group type: EXPERIMENTAL
Intervention: Risedronate sodium
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 21486181

Group type: EXPERIMENTAL
Intervention: Phase I periodontal therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (AMI without chronic periodontitis)
Number of subjects: 72
Study: 19808745

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia / analgesia (EA) group
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia with i/v opiate analgesia (GA) group
Number of subjects: 60
Study: 16917115

Group type: EXPERIMENTAL
Intervention: Sildenafil (0.4 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14687247

Group type: EXPERIMENTAL
Intervention: Very low-protein diet supplemented with essential amino acids and ketoacids (Ketodiet)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy sex- and age-matched subjects (Control)
Number of subjects: 28
Study: 11397619

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 gram IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg orally
Number of subjects: 0
Study: 9428435

Group type: EXPERIMENTAL
Intervention: ESWL+push back
Number of subjects: 30

Group type: COMPARATOR
Intervention: ESWL in situ
Number of subjects: 30
Study: 8098446

Group type: EXPERIMENTAL
Intervention: Ovarian ablation
Number of subjects: 332

Group type: COMPARATOR
Intervention: CMF chemotherapy
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Prednisolone 7.5 mg daily for 5 years
Number of subjects: 332

Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 332
Study: 2892255

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg at bedtime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nizatidine 25 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29708031

Group type: EXPERIMENTAL
Intervention: RemoweLL device (Group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard device (Group A)
Number of subjects: 44
Study: 27150898

Group type: EXPERIMENTAL
Intervention: PMMA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetal (AC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Polyamide (PA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 25260983

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium suppository
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Acetaminophen suppository
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no analgesic)
Number of subjects: 180
Study: 23475442

Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope with stylet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope without stylet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with stylet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope without stylet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Number of subjects: 120
Study: 21797795

Group type: EXPERIMENTAL
Intervention: Combination of angiotensin II receptor antagonist (ARB) and controlled-release nifedipine (20-40 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fixed-dose combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Number of subjects: 18